)P 3 or PIP 3 ) mediates signalling pathways as a second messenger in response to extracellular signals. Although primordial functions of phospholipids and RNAs have been hypothesized in the 'RNA world', physiological RNA-phospholipid interactions and their involvement in essential cellular processes have remained a mystery. We explicate the contribution of lipid-binding long non-coding RNAs (lncRNAs) in cancer cells. Among them, long intergenic non-coding RNA for kinase activation (LINK-A) directly interacts with the AKT pleckstrin homology domain and PIP 3 at the single-nucleotide level, facilitating AKT-PIP 3 interaction and consequent enzymatic activation. LINK-A-dependent AKT hyperactivation leads to tumorigenesis and resistance to AKT inhibitors. Genomic deletions of the LINK-A PIP 3 -binding motif dramatically sensitized breast cancer cells to AKT inhibitors. Furthermore, meta-analysis showed the correlation between LINK-A expression and incidence of a single nucleotide polymorphism (rs12095274: A>G), AKT phosphorylation status, and poor outcomes for breast and lung cancer patients. PIP 3 -binding lncRNA modulates AKT activation with broad clinical implications.
resistance is critical for the development of strategies to treat or prevent resistant tumours.
Long non-coding RNAs (lncRNAs) play emerging roles in cell signalling pathways via interactions with protein partners [18] [19] [20] [21] [22] . The observation that RNA molecule association with cellular membranes is involved in formation of the Escherichia coli signal recognition particle 23 and regulation of Saccharomyces cerevisiae cell membrane permeability 24 supports the notion that RNA-lipid interactions might be physiologically important. However, bona fide RNA-phospholipid interactions remain unidentified. The identification of lncRNA-lipid interactions introduces lncRNAs as mediators of signalling pathways relevant to homeostasis and disease.
We show that a lncRNA named long intergenic non-coding RNA for kinase activation (LINK-A, also LINC01139) directly and specifically interacts with AKT and PIP 3 . The LINK-A-AKT and -PIP 3 interactions facilitate AKT recruitment and consequent activation. We identified the single nucleotides of LINK-A required for PIP 3 and AKT bindings. LINK-A-dependent AKT hyperactivation leads to tumorigenesis and resistance to AKT inhibitors. Genomic deletion of the LINK-A PIP 3 -binding motif in resistant cells restores MK2206 sensitivity, suggesting that LINK-A confers resistance to targeted therapy in breast cancer. Furthermore, amplification of the LINK-A locus in cancer patients substantiates its promise as a clinical biomarker. The meta-analysis uncovered the association between LINK-A expression and high incidence of a single nucleotide polymorphism (SNP; rs12095274:A>G), which further correlated with AKT phosphorylation status, people of African descent, and poor outcomes for breast cancer patients. Our data reveal a PIP 3 -dependent role for lncRNA in mediating AKT activation and conferring resistance to AKT inhibitors. Clinically, preventing resistance is favourable to treating resistance after it develops; thus, if LINK-A overexpression is observed in patients that develop resistance to AKT inhibitors, this provides a rationale for targeting LINK-A, either alone or in combination with AKT inhibitors, when treating breast tumours.
RESULTS

Identification of lipid-binding lncRNAs
To identify RNAs that naturally associate with cellular lipids, we isolated lipid fractions and bound RNAs from triple-negative breast cancer (TNBC) patient tissues. Fresh-frozen TNBC tissues and their normal counterparts 18 were subjected to total RNA extraction or, in parallel, to whole-cell fractionation via hydrostatic pressure cycling to form a lipid-containing upper phase, a denatured protein-containing lower phase, and an insoluble fraction containing DNA and RNA [25] [26] [27] . The total RNAs and the RNAs from the lipid fraction were analysed by LncRNA Array (Fig. 1a and Supplementary Table 1 ). Using a fourfold cutoff threshold (tumour versus normal) and by overlapping the total lncRNA array with the lipid-bound lncRNA array, we identified 9 of 550 lncRNAs (about 1.6%) that were associated with the lipid fraction ( Fig. 1b) . We defined the relative lipid enrichment by comparing the normalized density of the total array with that of the lipid-bound array (Lipid/Total) and found that while all 9 lncRNAs showed consistent lipid enrichment in both normal (N_Lipid/Total) and TNBC tissues (T_Lipid/Total), LINC01139 exhibited the highest lipid enrichment ( Fig. 1c and Supplementary Fig. 1a ). Furthermore, LINC01139 is upregulated in TNBC compared with its normal counterpart ( Supplementary Fig. 1b ). Using lipid-coated-bead 28 pulldown followed by quantitative PCR with reverse transcription (RT-qPCR) assay, we confirmed that 7 of the 9 lncRNAs exhibited specificities for various phospholipids (>2-fold enrichment compared with control beads). Among them, LINC01139 (renamed LINK-A) showed enrichment for phosphatidylcholine (PC) and PIP 3 , with minimal cross-reaction with phosphatidylinositol-4,5-biphosphate (PIP 2 ) ( Fig. 1d and Supplementary Fig. 1c,d) .
Characterization of LINK-A as a PIP 3 -binding lncRNA LINK-A has been characterized as a long intergenic non-protein coding RNA 19, 29 . We first validated the LINK-A-PIP 3 /PC interaction using lipid strips 30 ; we used lncRNAs with comparable length as the controls, including BCAR4 (1,309 bp), Linc-131 (1,353 bp), and H19 (2,322 bp) and they did not interact with lipids ( Fig. 1e ). Consistent with lipid-coated-bead pulldown assay (Fig. 1d ), SNHG9 and RP11-383G10.5 exhibited specific binding to PA and cardiolipin respectively ( Fig. 1e) . We then performed a fluorescence resonance energy transfer (FRET) assay 31 using soluble, fluorophore-conjugated PIP 3 (15 nM) as the donor and Alexa-555-streptavidin-labelled LINK-A or RP11-383G10.5 (0-200 nM) as the acceptors (Fig. 1f , upper panel). When excited at 475 nm, we observed robust FRET signals as indicated by an increase of acceptor emissions at 570 nm with concomitant decreases in the donor emission centred around 513 nm ( Fig. 1f, lower panel) , signifying specific physical contact between LINK-A and PIP 3 in vitro. The addition of LINK-A, but not RP11-383G10.5 (0-400 nM), to PIP 3 led to a reduction in the emission intensity ( Fig. 1g and Supplementary Fig. 1e ). These data allow for calculation of the binding affinity of the LINK-A-PIP 3 interaction in solution (K d = 110.7 ± 37 nM) ( Fig. 1h) , which was stronger than or similar to known protein-PIP 3 interactions (200 nM to 2 µM) 32, 33 . The cardiolipin-binding lncRNA RP11-383G10.5 exhibited no detectable binding with PIP 3 (Fig. 1h ).
Next, we mapped the LINK-A sequences required for PC and PIP 3 binding using a dot-blot assay 18, 19 (Fig. 1i ). Pre-incubation of biotinylated LINK-A with PC-or PIP 3 -coated beads protected the lipid-bound LINK-A sequences from RNase I digestion and hybridization of these RNA sequences to dot blot showed streptavidin signals on dots A5 (nucleotides (nt) 241-300) and D1 (nt 1081-1140) respectively ( Fig. 1i ), indicating that these regions are responsible for lipid binding. Deletion of the PC-and PIP 3 -binding motifs of LINK-A (referred to as PC and PIP 3 LINK-A) abolished its interaction with PC and PIP 3 respectively (Fig. 1j ). Amplified luminescent proximity homogeneous assay (Alpha) 34, 35 was applied to calculate the LINK-A-PIP 3 -binding affinity, finding that PIP 3 binds specifically to LINK-A with K d = 142 nM ( Supplementary Fig. 1f,g) . Competition with short RNA sequences of the PIP 3 -binding motif (nucleotides 1,081-1,140) but not the PC-binding motif revealed reduced PIP 3 binding to LINK-A ( Supplementary Fig. 1g ), indicating that nucleotides 1081-1140 of LINK-A are required for PIP 3 binding.
To visualize LINK-A association with phospholipids in the context of a membrane, we generated giant unilamellar vesicles (GUVs) composed of 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC) alone or DOPC with PIP 3 (1.5% mol) [36] [37] [38] surface of the DOPC-containing GUVs ( Fig. 2a and Supplementary  Fig. 2a -c). LINK-A PC was recruited to the surface of the GUVs as clusters, which is consistent with the notion that PIP 3 segregates into enriched regions within the plasma membrane 39 . The PIP 3 analogue D-myo-inositol-1,3,4,5-tetrakisphosphate (IP 4 ) but not D-myo-inositol-1,4,5-trisphosphate (IP 3 ) (100:1 molar ratio to PIP 3 ) abolished this interaction ( Fig. 2a ). Using PIP arrays, we observed that LINK-A exhibited association with PIP 3 , weaker binding to PIP 2 , and minimal interaction with other PIPs (Fig. 2b ). This interaction was abolished in the presence of soluble PIP 3 or IP 4 (100:1 molar ratio to RNA) but not IP 3 (Fig. 2b) .
To examine the LINK-A-PIP 3 interaction in vivo, we took advantage of the MS2-TRAP (MS2-tagged RNA affinity purification) system 40, 41 by expressing MS2-tagged FL LINK-A or PIP 3 deletion mutant in MDA-MB-231 cells and analysing the protein-RNA-lipid complex pulled down by GST antibodies ( Supplementary Fig. 2d ,g and Fig. 2c , upper panel). By pulling down GST-MS2 ( Fig. 2c , lower panel), we retrieved similar levels of MS2-LINK-A from cells treated with dimethylsulfoxide (DMSO), permeable PI(1,4,5,6)P 4 or PI(1,3,4,5,6)P 5 (Fig. 2d ). MS2-LINK-A-associated PIP 3 was detected in the presence of DMSO or PI(1,4,5,6)P 4 ( Fig. 2e ) by PIP 3 mass enzyme-linked immunosorbent assay (ELISA) 42 . Conversely, in the presence of PI(1,3,4,5,6)P 5 , MS2-LINK-A-PIP 3 interaction was impaired ( Fig. 2e ), suggesting that the 3 -phosphate of PIP 3 is important for LINK-A binding. Furthermore, the MS2-tagged LINK-A PIP 3 failed to associate with PIP 3 (Fig. 2f-h) . These observations were not due to aberrant PI3K activity or level as revealed by PI3-kinase activity ELISA and PI3K immunoblotting respectively ( Supplementary Fig. 2e ,f,h,i). Additionally, LINK-A binds to IP 4 with an affinity (K d = 210 nM) similar to that for PIP 3 ( Supplementary  Fig. 3a,b ), indicating that while the 3 , 4 and 5 phospho groups of PIP 3 are all required, the 3 phospho group is the most important for LINK-A binding. RNA immunoprecipitation (RIP) assay using a PIP 3 antibody showed the LINK-A-PIP 3 interaction in vivo, which was abolished by the PI3K inhibitor LY294002 ( Supplementary Fig. 3c,d) .
The ErbB receptor tyrosine kinases activate PI3K and downstream AKT in a ligand-dependent manner 43, 44 . We reasoned that LINK-A-PIP 3 interaction is triggered by EGF stimulation. We observed that LINK-A was enriched in the membrane fraction on EGF treatment ( Supplementary Fig. 4a -c). Rescue experiments after LINK-A was knocked down by Locked Nucleic Acids (LNA) and followed by reintroduction of LNA-resistant FL LINK-A or LINK-A deletion mutants ( PC and PIP 3 respectively) ( Supplementary Fig. 4d ,e) indicated that depletion of LINK-A diminished LINK-A-PIP 3 interaction, which was rescued by FL or PC LINK-A but not PIP 3 LINK-A ( Supplementary Fig. 4f ). These results validate that LINK-A binds PIP 3 in a specific manner.
LINK-A facilitates AKT recruitment to PIP 3 and enzymatic activation of AKT
Hyperactivation of PI3K and AKT-PIP 3 interaction directs tumour growth and metastasis 45, 46 . We examined the role of LINK-A in AKT-PIP 3 interaction using lipid strips, finding that although recombinant AKT associated with PIP 3 in vitro, the presence of FL LINK-A enhanced the AKT-PIP 3 interaction in a PIP 3 -bindingdependent manner (Fig. 3a) . We further measured the K d of the AKT-PIP 3 interaction in the presence or absence of LINK-A. Using Alpha-based saturation and competition assays, we calculated that K d for the AKT-PIP 3 interaction without LINK-A is between 304-349 nM, which is consistent with the literature 32 (Fig. 3b-d ). AKT exhibited minor binding with PIP 2 (K d = 1,243 nM) and no binding with PI(4)P (K d = ND (not detected)) ( Fig. 3c , middle and right panels). In the presence of FL but not PIP 3 LINK-A, AKT-PIP 3 binding was enhanced 7-fold (K d = 46.1 nM) ( Fig. 3d ). These data suggest that AKT, PIP 3 and LINK-A form a complex on ligand stimulation, which was confirmed by RIP assay (Fig. 3e ). Furthermore, knockdown of LINK-A impaired AKT phosphorylation at Thr308 and Ser473, under both basal and EGF stimulation conditions, leading to impaired AKT activation as revealed by diminished phospho-GSK-3β ( Fig. 3f,g) . LINK-A depletion also abolished AKT-PIP 3 interaction in vivo ( Fig. 3h ). Next, we examined whether LINK-A modulates AKT kinase activity, finding that LINK-A knockdown impaired AKT kinase activity in EGF-treated cells and overexpression of FL but not PIP 3 LINK-A rescued AKT activation (Fig. 3i ). The presence of FL but not PIP 3 LINK-A enhanced AKT enzymatic activity in a polyPIPosomes-mediated in vitro assay 6 ( Supplementary Fig. 4g ). These data suggest that LINK-A enhances AKT-PIP 3 interaction to facilitate the AKT enzymatic activation.
Molecular mechanisms of LINK-A-PIP 3 -AKT interactions
Structural analysis has shown that RNA loops may be important for protein associations 47, 48 . The secondary structure of LINK-A is involved in its interaction with BRK and LRRK2 19 (Supplementary Fig. 5a , black circle) and possibly in PIP 3 interaction (Supplementary Fig. 5a , red circle). The 60-nt RNA oligonucleotides of the PIP 3 -binding motif (nt 1081-1140) harbours an identical stemloop structure based on computational calculation ( Supplementary  Fig. 5b , red circle). We synthesized digoxigenin (DIG)-labelled 18nt RNA oligonucleotides harbouring wild-type LINK-A sequence (nt 1100-1117, 5 -CAGGGUAGACUCGCUCUG-3 , loop underlined) ( Fig. 4a ), RNA oligonucleotides with the 4 central nucleotides of the loop removed or single nucleotides of the loop region mutated ( Supplementary Fig. 5c ). Alpha assay indicated an adequate interaction between wild-type LINK-A and PIP 3 in vitro, with K d of 2.6 µM ( Fig. 4b ). Deletion of the loop region ( 2-5) abolished RNA-PIP 3 interaction ( Fig. 4b ). Interestingly, RNA oligonucleotides with C to A mutations at either position 4 or 6 showed undetectable interaction with PIP 3 (Fig. 4b ), suggesting the importance of nucleotides C 1109 and C 1111 of LINK-A in mediating PIP 3 binding. RNA-PIPs overlay assay also exhibited undetectable association of PIP 3 with either LINK-A C1109A (referred to as 4A) or LINK-A C1111A (referred to as 6A) ( Fig. 4c and Supplementary Fig. 5d ). Using a similar strategy, the 18-nt RNA oligonucleotide representing LINK-A (nt 1100-1117) directly associated with recombinant AKT in vitro ( Fig. 4e ). Nucleotide A 1108 at position 3 of the stem-loop was required to mediate LINK-A-AKT interaction ( Fig. 4e ). LINK-A A 1108 to C mutant (referred to as 3C) exhibited similar binding to PIP 3 as wild-type LINK-A ( Fig. 4b ), but impaired binding to AKT in vitro ( Fig. 4d ).
Crystallographic analysis indicated that the AKT PH domain harbours three variable loops (referred to as L1: amino acids (aa) 16-21; L2: aa 40-52; L3: aa 80-81) ( Fig. 4f) 49 
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We further generated MS2-tagged LINK-A 3C, 4A and 6A mutants for an MS2-TRAP assay (Fig. 4h ). Compared to WT LINK-A, 3C exhibited a similar interaction with PIP 3 ; however, PIP 3 , 4A and 6A mutants failed to interact with cellular PIP 3 as revealed by PIP 3 mass ELISA (Fig. 4h) , although similar amounts of MS2-tagged LINK-A were retrieved ( Supplementary Fig. 5e ). We also determined that LINK-A PIP 3 and 3C mutants exhibited impaired association with AKT, while 4A and 6A were as competent as WT LINK-A (Fig. 4i) . Therefore, we identified the single nucleotides of LINK-A that are required for PIP 3 and AKT binding respectively and provide structural evidence underlying LINK-A-facilitated AKT-PIP 3 interaction.
Functional relevance of LINK-A-PIP 3 interaction in AKT activation
We determined that there are roughly 150 copies of the LINK-A per MDA-MB-231 cell ( Supplementary Fig. 6a,b ) and the copy number was reduced to 10-15 per cell by LNA, which was restored by exogenously expressed LINK-A or the PIP 3 deletion mutant ( Supplementary Fig. 6b ). LINK-A knockdown abolished EGFinduced AKT phosphorylation and cell proliferation ( Supplementary  Fig. 6c,d) . Reintroduction of FL LINK-A, but not the PIP 3 mutant, restored AKT/GSK-3β phosphorylation and tumour cell proliferation ( Supplementary Fig. 6c,d) . Fewer than 10 copies of LINK-A are found in normal mammary gland epithelial cells (MCF-10A). Stably expressing FL LINK-A in MCF-10A cells, to about 150 copies per cell, amplified AKT/GSK-3β phosphorylation and cell proliferation ( Supplementary Fig. 6e-g) .
We used a pair of colorectal cancer cell lines (DLD-1 PIK3CA +/+ and DLD-1 PIK3CA +/− ) in which PIP 3 levels were genetically altered. Parental DLD-1 PIK3CA +/+ cells harbours about 0.6 pmol PIP 3 per 5 × 10 6 cells before EGF stimulation, and about 2.8 pmol PIP 3 after EGF stimulation (Fig. 5a ). In DLD-1 PIK3CA +/− cells, the PIP 3 level per 5 × 10 6 cells was about 0.2 pmol (Fig. 5a) . Consistently, the EGFinduced AKT phosphorylations at Thr308 and Ser473 were abolished in DLD-1 PIK3CA +/− cells (Fig. 5b) . We also measured the copy number of LINK-A in DLD-1 PIK3CA +/+ and PIK3CA +/− cells, finding that both cell lines harboured about 10 copies of LINK-A (Fig. 5d ). We then chose to deliver the in vitro-transcribed andcapped wild-type LINK-A or mutant intracellularly into DLD-1 cells (Fig. 5c ). We attempted to deliver 150 copies of LINK-A, and RT-qPCR indicated that single DLD-1 cells contained about 120 copies of LINK-A after delivery (Fig. 5d ), of which wild-type LINK-A, but not the PIP 3 mutant, dramatically enhanced the EGF-induced AKT phosphorylation (Fig. 5e ).
Furthermore, in DLD-1 PIK3CA +/− cells, delivery of PIP 3 (3 pmol per 5 × 10 6 cells) increased cellular PIP 3 to about 2.2 pmol per 5 × 10 6 cells (Fig. 5c,f) . However, restored cellular PIP 3 levels marginally mediated EGF-induced AKT phosphorylation (Fig. 5h ). Delivery of LINK-A (150 copies per cell) alone minimally affected AKT phosphorylation (Fig. 5g,h) , while combined delivery of PIP 3 and LINK-A robustly enhanced AKT phosphorylation ( Fig. 5f-h) . To determine whether LINK-A-PIP 3 interaction but not either alone is important in enhancing the activation of the EGF-AKT pathway, we delivered WT LINK-A, or PIP 3 or PC mutants to DLD-1 PIK3CA +/− cells in the presence of PIP 3 (Fig. 5i-k) . Despite comparable delivery efficiencies, FL LINK-A but not PIP 3 mutants enhanced EGF-triggered, PIP 3 -mediated AKT phosphorylation (Fig. 5k) . Consistently, co-delivery of PIP 3 with WT LINK-A, but not 3C, 4A or 6A mutants, in DLD-1 PIK3CA +/− cells led to robust AKT phosphorylation ( Fig. 5l and Supplementary Fig. 6h,i) . Furthermore, delivery of ∼120 copies of WT LINK-A, but not 3C, 4A or 6A mutants, enhanced recruitment of AKT to PIP 3 in vivo following EGF stimulation in DLD-1 PIK3CA +/+ cells (Fig. 5m,n and Supplementary Fig. 6j ). Taken together, our data indicate that about 150 copies of LINK-A is functionally sufficient to facilitate EGFtriggered AKT-PIP 3 interaction and subsequent AKT activation.
LINK-A confers resistance to AKT inhibitors
There are four types of inhibitor targeting the AKT PH domain that are being developed: phosphatidylinositol ether lipid analogues, alkyl-phospho-lipids or other inositol phosphate derivatives, such as perifosine 55 ; sulfonamides 56 ; purine/pyrimidine analogues, such as triciribine 57 ; and allosteric compounds, including MK2206 58 . Since LINK-A enhances AKT activation by interacting with the PH domain of AKT and PIP 3 , high LINK-A expression may antagonize the effect of AKT inhibitors including perifosine and MK2206. We confirmed that perifosine and MK2206 inhibited PIP 3 -AKT interaction with an IC 50 value of 8.1 nM and 28.7 nM respectively, while AKT kinase domain inhibitors exhibited minimal effects (Fig. 6a) . In vitro, the presence of FL LINK-A, but not LINK-A PIP 3 , antagonized the inhibitory effect of MK2206 and perifosine by 753-and 140-fold respectively (IC 50 = 6.4 µM and 4.8 µM) (Fig. 6b,c) . Then, we genetically deleted the PIP 3binding motif (PIP 3 -BM) of LINK-A using CRISPR/Cas9 technology in MDA-MB-231 cells ( Fig. 6d and Supplementary Fig. 7a-d) . Two independent single-cell clones of LINK-A PIP 3 -BM −/− cells showed that AKT failed to interact with PIP 3 (Fig. 6e-f ), leading to diminished AKT phosphorylation (Fig. 6g ). We performed an Alpha assay to quantify the EGF-induced AKT phosphorylation in PIP 3 -BM −/− cells by measuring the amounts of total AKT and phospho-AKT simultaneously, in response to a series of threefold dilutions of EGF (Fig. 6h) . The EGF concentration that induced 50% phosphorylation of AKT over total AKT was defined as EGF EC 50 (Fig. 6i) . In LINK-A PIP 3 -BM +/+ cells, about 11.0 nM of EGF was required to induce 50% AKT phosphorylation, while in PIP 3 -BM −/− cells 94.5 nM of EGF was needed (Fig. 6i ). In rescue experiments, intracellularly delivered WT LINK-A restored sensitivity to EGF stimulation; however, LINK-A 3C, 4A and 6A mutants failed to rescue this phenotype (Fig. 6i ). Pharmacologic validation was performed using 1:2 dilution of MK2206 under the EGF EC 80 (200 nM) condition (Fig. 6j) . In LINK-A PIP 3 -BM +/+ cells, 16.2 µM MK2206 was needed to half the AKT phosphorylation (Fig. 6j ). However, in LINK-A PIP 3 -BM −/− cells, only 65.7 nM of MK2206 was sufficient to inhibit AKT activation (Fig. 6j ). Intracellular delivery of WT LINK-A, but not 3C, 4A or 6A mutants, into LINK-A PIP 3 -BM −/− cells restored resistance to MK2206 (Fig. 6j ).
Next, we used a three-dimensional tumour spheroid assay 59 to evaluate the impact of LINK-A-PIP 3 interaction on AKT inhibitor efficacy (Fig. 7a ). About 11.7 µM MK2206 was needed to inhibit LINK-A PIP 3 -BM +/+ tumour spheroid growth (Fig. 7b) . However, only about 50 nM MK2206 was sufficient to inhibit LINK-A PIP 3 -BM −/− spheroid growth by half (Fig. 7b) . The cell viability index indicated that 214 µM perifosine was needed to induce 50% cell death of LINK-A PIP 3 -BM +/+ spheroids. LINK-A PIP 3 -BM −/− spheroids were sensitized to perifosine by about 20,000-fold, with an IC 50 value of 11.3 nM (Fig. 7c) . For LINK-A PIP 3 -BM −/− cells, only 25 nM perifosine was sufficient to inhibit AKT-PIP 3 interaction in vivo (Fig. 7d,e ). Furthermore, 50 nM MK2206 or 25 nM perifosine efficiently inhibited proliferation and invasion of LINK-A PIP 3 -BM −/− spheroids ( Fig. 7f-i) , while the same dose elicited an undetectable effect on LINK-A PIP 3 -BM +/+ spheroids (Fig. 7f-i) . These data indicate that LINK-A-PIP 3 interaction confers resistance to AKT inhibitors.
Genetic mutation and amplification of LINK-A correlate with AKT phosphorylation in human cancer By analysing somatic copy number variants amongst clinical samples, we found that the LINK-A gene locus is amplified in multiple cancer types including breast cancer (Fig. 8a) . We also identified genetic mutations within or adjacent to the LINK-A gene locus in breast and lung cancer patient samples ( Supplementary Fig. 8a-d) . Intriguingly, mutation of a single SNP downstream of the LINK-A transcription unit correlated with LINK-A expression and breast cancer patient outcomes (Fig. 8b,c and Supplementary Fig. 8a) . Likewise, the NCBI dbSNP Reference SNP (refSNP) Cluster Report showed that African women with advanced breast cancer exhibit the highest incidence of double allele mutations of this SNP compared with Europeans and Asians (Fig. 8d) .
We assessed LINK-A expression in breast cancer tissue samples (clinical information listed in Supplementary Table 3 ) by RNAscope, finding that high LINK-A expression correlated with breast cancer malignancy and unfavourable outcomes ( Supplementary Fig. 8e,f) . Our data suggest strong correlation between LINK-A expression and AKT phosphorylation at Thr308 and Ser473 (r 2 = 0.7392 and 0.6659, P < 0.0001 respectively) (Fig. 8e,f and Supplementary Fig. 8g ). We confirmed that tissue samples with single or double allele mutations (A-G) of the aforementioned LINK-A SNP exhibited elevated LINK-A expression and increased AKT phosphorylation at Thr308 (Fig. 8g,h) . These data indicate the importance of LINK-A in regulating the PIP 3 -AKT signalling pathway in human cancer.
Finally, we determined that LINK-A is required for cell proliferation and anti-apoptosis ( Supplementary Fig. 8h-k) . We next examined the therapeutic value of LNAs targeting LINK-A in an xenograft mouse model of breast cancer. LNA administration inhibited in vivo tumour glucose uptake revealed by positron emission tomography (PET) scanning (Fig. 8i,j) . Tumour burden was considerably diminished with LINK-A LNA treatment compared with the control group (Fig. 8k ), suggesting that by using LNAs to block LINK-A in vivo, glycolysis and tumorigenesis can be repressed in breast cancer cells.
DISCUSSION
We have identified a cohort of lncRNAs that associates with various membrane phospholipids, including PC and PIP 3 . Our data show that LINK-A-PIP 3 interaction facilitates AKT activation on EGF stimulation, indicating that this interaction is important in both homeostasis and cancer. The association between the AKT PH domain and PIP 3 may cause a conformational change in AKT, making the phosphorylation sites accessible to its activating kinases. Our data demonstrate that LINK-A promoted the recruitment of AKT to PIP 3 , which enhances AKT phosphorylation.
Many key regulators exhibit high binding affinities for PIP 3 , with lower binding affinities for other PIPs 33 . Our data indicate that LINK-A exhibits strong PIP 3 -binding affinity with a K d around 111.7 nM in the liquid phase. This binding affinity is similar to or stronger than that of many known PIP 3 -binding proteins. For example, PLC-δ1 and AKT bind PI(1,4,5)P 3 with K d 210 nM and 400 nM respectively 32, 60 . Therefore, the interaction between LINK-A and PIP 3 is probably biologically relevant.
The consequence of LINK-A-PIP 3 interaction is intriguing. As a proof of concept, we examined the AKT kinase activity in the presence of both LINK-A and PIP 3 . Our data demonstrate that in vitro, LINK-A promoted AKT recruitment to PIP 3 ; in vivo, LINK-A-PIP 3 and LINK-A-AKT interactions are required for AKT phosphorylation. LiP-LC-MS analysis provides further support that LINK-A associates with the L1 and L2 loops of the AKT PH domain, which may elicit a conformational change, facilitating L1 loop interaction with PIP 3 , given that the 3 phosphate of IP 4 associates with the L1 loop 50 . These effects further stabilize the AKT-PIP 3 interaction, leading to a more 'open' structure and enhanced AKT enzymatic activation. It should be noted that LiP-LC-MS provides only initial evidence for potential conformational change of target protein under different conditions. This research will pave the way for ultimate structural resolution of RNA-lipid by nuclear magnetic resonance (NMR) and/or X-ray crystallography.
LINK-A is highly expressed in breast cancer and correlated with outcomes of breast cancer patients. In human cancer, LINK-A is likely to be upregulated by two mechanisms: genetic amplification and disease-related SNPs that modulate LINK-A expression. Our study suggests that cancer with high LINK-A expression may exhibit resistance to AKT inhibitors, with implications for clinical trials and the development of inhibitors. LINK-A could possibly serve as a biomarker to predict resistance to AKT PH domain inhibitors. Breast cancer patients could be stratified on the basis of LINK-A expression levels to help determine an individual's sensitivity to AKT inhibitor treatment. These findings demonstrate the importance of lncRNAs in cancer biology and signify the physiological relevance of RNA-PIP 3 interaction.
METHODS
Methods, including statements of data availability and any associated accession codes and references, are available in the online version of this paper.
Note: Supplementary Information is available in the online version of the paper DOI: 10.1038/ncb3473 METHODS Tissue samples. Fresh-frozen triple-negative breast cancers and adjacent normal tissues were purchased from Asterand Bioscience and clinical parameters were listed in a previous study 18 . Two sets of fresh-frozen breast cancer tissues (Nanjing Cohort and Duke Cohort) were collected from Yixing People's Hospital and Duke University respectively. The study protocol was approved by the Institutional Review Board of Nanjing Medical University and Duke University Health System. All tissue samples were collected in compliance with informed consent policy. Detailed clinical information is listed in Supplementary Table 3 .
Cell lines, transfection, treatments and cellular assays. The human breast cancer cell lines MDA-MB-231 and MDA-MB-468 and the human mammary gland epithelial cell line MCF-10A were purchased from the American Type Culture Collection (ATCC). DLD-1 PIK3CA +/+ and PIK3CA +/− cells were purchased from Sigma-Aldrich. All cell lines were authenticated by autosomal STR profiles provided by the Characterized Cell Line core (MD Anderson Cancer Center). All cell lines were free of mycoplasma contamination, tested by vendors using MycoAlert kit from Lonza. siRNA and plasmid transfections were performed using DharmaFECT4 (Dharmacon) and Lipofectamine 3000 (Life Technologies) respectively. None of the cell lines used was found in the database of commonly misidentified cell lines that are maintained by ICLAC and NCBI Biosample. For growth factor treatment, cells were serum starved for 24 h followed by treatment with the indicated concentration of EGF (Peprotech) for 20 min. For competition binding assay, cells were pretreated with 100 µM cell-permeable PI (1, 4, 5, 6 )P 4 or PI(1,3,4,5,6)P 5 for 2 h. For pharmacologic inhibition, cells or tumour spheroids were treated with MK2206 or perifosine (SelleckChem) for the indicated times and at the indicated concentrations. Membrane and cytoplasmic fractions were prepared using the ReadyPrep Protein Extraction Kit (Membrane I) (Bio-Rad). Immunoblotting, immunoprecipitation, cell proliferation and apoptosis assays were performed as previously described 19 . LINK-A PIP 3 -binding motif knockout cell lines were generated using the CRISPR/Cas9 genome editing system by the Gene Editing/Cellular Model Core Facility (MD Anderson Cancer Center).
RNA biology assays. All lncRNAs were in vitro transcribed and purified as previously described 18, 19 . To isolate lipid-bound RNAs, total lipids from the freshfrozen triple-negative breast cancers and their adjacent normal tissues were extracted by the Barocycler NEP3229 using the Pressure Enhanced Systems Biology Kit (Pressure BioScience). The lipid-bound RNAs were further purified by Trizol. LncRNA array hybridization and data analysis were performed as previously described 18 . RNAScope, RIP assay, in vitro RNA-lipid binding coupled with dotblot assay, immunohistochemistry and image quantification were performed as previously described 18, 19 . Intracellular delivery of 3 -0-Me-m7G(5 )ppp(5 )G-capped LINK-A was performed using the TransIT-mRNA Transfection Kit (Mirus Bio). The MS2-TRAP assay was performed as described previously 40, 41 .
Lipid reagents, antibodies and siRNA, shRNA and LNA. All reagents for lipid experiments were purchased from Echelon Biosciences. PIP 3 was quantified using a PIP 3 mass ELISA kit (Echelon Biosciences). PI3K activity was measured using PI3-Kinase Activity ELISA (Echelon Biosciences). Intracellular PIP 3 delivery was performed using PI(3,4,5)P 3 Shuttle PIP Kit (Echelon Biosciences).
The antibodies used in this study are summarized in Supplementary Table 4 . Commercially available Lincode SMARTpool siRNA targeting LINK-A (R-027622) was used in this study. The oligonucleotides for shRNA targeting LINK-A were designed on the basis of Lincode SMARTpool siRNA sequence and cloned into pLKO.1-Puro vector. LNAs targeting LINK-A or a scrambled sequence were designed and synthesized by Exiqon. Detailed sequences are listed in Supplementary  Table 5 .
Cloning procedures. Mammalian expression vectors for full-length LINK-A and various deletion mutants were constructed by subcloning the gene sequences into pCDNA3.1 (+) backbone (Life Technologies), pBabe retroviral expression vector, or MS2-24x-pCNDA vector 41 . To generate the LNA no. 5-resistant LINK-A expression vectors used in the rescue experiments, the LNA no. 5 targeting sequence ACA GCT CAT TTA TCC A was mutated to ACA GGC GAT TTA TCC A. All single-point and deletion mutations were generated using the QuikChange Lightning Site-Directed Mutagenesis Kit (Agilent Technologies). Detailed oligonucleotide sequences are listed in Supplementary Table 5 .
RNA/protein-lipid overlay assay. Membrane lipid strip or PIP array was blocked with RNA-lipid binding buffer (50 mM HEPES pH 7.0, 50 mM NaCl, 5 mM MgCl 2 and 2 mM CaCl 2 ) supplemented with 3% BSA and 10 µg ml −1 yeast tRNA and then incubated with in vitro-transcribed RNAs (1 µg ml −1 ) in RNA-lipid binding buffer supplemented with 50 U ml −1 RNase inhibitor. The strip/array was washed three times with RNA-lipid binding buffer supplemented with 0.05% NP-40 and further incubated with Streptavidin-HRP. The strip/array was washed three times as described above and the bound RNA was detected by TMP precipitating reagent. For PIP competition experiments, D-myo-inositol 1,3,4,5-tetraphosphate (IP 4 ), D-myo-inositol 1,4,5-tetraphosphate (IP 3 ) or BODIPY FL-PIP 3 was added in RNA-lipid overlay assay at 100:1 molar ratio (lipid/RNA). For lipid-RNA-protein overlay assay, after blocking once and washing three times, the strip was further incubated with the indicated proteins followed by washes as described above. Strips were probed with the specific primary antibody followed by peroxidase-conjugated secondary antibodies.
Lipid-RNA pulldown assay. The lipid-coated beads were blocked with RNA-lipid binding buffer (see above) supplemented with 3% BSA, 10 µg ml −1 yeast tRNA, and lipid phosphate phosphatase inhibitors (XY-14, 3-α-aminocholestane, SF1670) followed by incubation with cell lysate. The beads were washed with RNA-lipid binding buffer supplemented with 0.05% NP-40. RNAs were eluted by RIP elution buffer (100 mM Tris-HCl pH 8.0, 10 mM EDTA, 1% SDS) and recovered by RNA Clean & Concentrator-5 (Zymo Research) for RT-qPCR analysis. The spectra were collected from 490 nm to 650 nm with slit widths set at 1 nm and the excitation wavelength set at 475 nm to minimize the contribution from directly excited acceptor emission. The spectrum of acceptor alone with the excitation at 475 nm was also recorded and used as the background to be subtracted from the Donor/Acceptor FRET spectrum. RNA-lipid vesicles binding assay. DOPC giant vesicles were prepared as previously described 37, 38 . The lipid vesicles composed of DOPC mixed with 1.5 mol% phosphatidylinositol-3,4,5-trisphosphate diC16 (PI(3,4,5)P 3 diC16) were generated as previously described 36 except the membranes were labelled with Nile Red (Life Technologies). RNAs in the RNA-lipid binding buffer (see above) were mixed with the cationic cyanide fluorescence dye YOYO-1 iodide (1 mM) (ThermoFisher). The suspension of lipid vesicles and the solution of RNA/YOYO were gently mixed at a volume ratio of 10:1 and mounted on glass coverslips. For PIP competition experiments, IP 4 or IP 3 was added in RNA-lipid vesicle binding assay at 100:1 molar ratio (IP 4 or IP 3 /PIP 3 ). Images were recorded with a Cooke SensiCam CCD (chargecoupled device) camera and processed with the use of the SlideBook software package (Intelligent Imaging Innovations).
RNA-lipid
Determination of K d for LINK-A-PIP 3 and AKT-PIP 3 interaction by Alpha assay.
A saturation curve was generated to determine the K d of the interaction between digoxigenin (DIG)-labelled LINK-A and biotin-labelled lipids in the Alpha format. The K d was further determined by a competition experiment in which unlabelled LINK-A was titrated from 0.4 mM to 0.05 nM. In detail, triplicate samples containing RNA and lipid at the indicated concentrations diluted in RNA-lipid binding buffer were transferred, 10 µl to each well, to a 1/2-area 96-well assay plate and then incubated at room temperature for 1 h. Ten microlitres of 5× anti-DIG AlphaLISA acceptor beads (100 µg ml −1 ) were added to each well. The plate was placed on an orbital shaker for 10 min and then incubated at room temperature for 1 h. Following incubation, 10 µl of 5× streptavidin donor beads (100 µg ml −1 ) were added to each well and incubated for 30 min at room temperature. The plate was read on the EnSpire Multimode Plate Reader (PerkinElmer). The saturation binding curve and competitive inhibition curve were generated based on Alpha signal readings by fitting to a nonlinear regression 'saturation binding' model and a 'log (inhibitor) versus response-Variable slope (four parameters)' model respectively (GraphPad Prism 7 software). For IC 50 determination, a serial twofold dilution of synthetic LINK-A competitors (sequences are listed in Supplementary Table 5 ) starting at 0.4 mM to 0.05 nM was supplied in RNA-lipid binding buffer and incubated with the reactions. IC 50 values were derived by a log (inhibitor) versus response-Variable slope (four parameters) model for competitive inhibition curve using GraphPad Prism 7 software.
To determine the K d value of the AKT-PIP 3 interaction with or without lncRNAs, Alpha assays were performed as described above. For saturation curve assay, 0.1 µM, 0.2 µM and 0.4 µM His-tagged recombinant AKT were incubated with a titration of biotin-PI(3,4,5)P 3 , -PI(4,5)P 2 , -PI(4)P as indicated. For the competition binding assay, the unlabelled PI(3,4,5)P 3 phospholipids were used as competitors at a series of twofold dilutions ranging from 33 µM to 0.25 nM. The K d values between AKT and PIP 3 were determined using GraphPad Prism 7 software.
Mapping of RNA-protein/lipid single nucleotide binding sites. LINK-A-PIP 3 interaction was assessed by AlphaLISA technology (Perkin Elmer). Synthetic DIGlabelled LINK-A and His 6 -AKT (ThermoFisher Scientific) and 5 µg ml −1 of anti-DIG donor beads and anti-6xHis AlphaLISA acceptor beads were incubated in RNAprotein binding buffer (50 mM Tris-HCl pH 7.9, 10% glycerol, 100 mM KCl, 5 mM MgCl 2 , 10 mM β-ME 0.1% NP-40) for 1 h. The Alpha signal was collected with an EnSpire Multimode Plate Reader. To determine the K d , increasing concentrations of unlabelled LINK-A were added in addition to the labelled RNA and protein or lipid. The K d values were derived from curve fitting based on a competitive-inhibitor model in GraphPad Prism 7.
Limited proteolysis (LiP) followed by LC-MS. LiP followed by LC-MS was modified on the basis of LiP-SRM analysis 52 . Briefly, bacterially expressed AKT PH domain (2 mg ml −1 ), alone or in the presence of PIP 3 (2 mM) and/or LINK-A wild-type or mutant oligonucleotides (2 mM), was incubated in buffer (20 mM HEPES, pH7.5, 150 mM KCl and 10 mM MgCl 2 ) and Protease K at room temperature for 5 min. The digestion was stopped by transferring the reaction mixture to a tube containing guanidine hydrochloride crystals to a final concentration of 7.4 M and by boiling for 3 min. The digestion mixtures were then subjected to complete tryptic digestion using immobilized trypsin (Promega). The peptides were subjected to LC-MS analysis at the Proteomic and Metabolic core facility of MD Anderson Cancer Center.
Determination of endogenous cellular AKT activation. Simultaneous detection of total and phosphorylated AKT levels in cellular kinase assays was performed using Alpha SureFire Total AKT1 and AKT1 (p-Ser473) assay kits (PerkinElmer). Data normalization was performed by dividing the raw Alpha signal generated for p-AKT by the raw Alpha signal for total AKT and multiplying by 100, which represents the percentage of AKT activation.
In vitro and in vivo AKT kinase assay. For in vitro AKT kinase activity, 20 ng of recombinant AKT, in vitro-transcribed LINK-A wild-type or PIP 3 -binding domain deletion mutant, and/or PIP 3 -containing polyPIPosomes (Echelon Biosciences) were incubated in a 1:1:1 molar ratio. For the in vivo AKT kinase assay, the cell lysates were extracted from MDA-MB-231 cells with the indicated treatments and the AKT kinase activity was measured by a non-radioactive AKT kinase activity kit (Enzo Life Sciences). SNP genotyping assay. Genomic DNA from fresh-frozen breast cancer tissues was extracted, purified, and further detected by real-time PCR using TaqMan Sampleto-SNP Kit (ThermoFisher).
Three-dimensional spheroid proliferation/viability and invasion assay.
Spheroid growth and invasion of parental MDA-MB-231 and its genomically edited derivative cells were conducted using the Cultrex 3-D Spheroid Fluorometric Proliferation/Viability Assay kit and Cultrex 3D Spheroid BME Cell Invasion Assay kit (Trevigen) respectively according to the vendor's instruction.
In vivo tumorigenesis and glucose uptake study. All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. Female athymic Nu/Nu mice (4-6 weeks old) arriving in our facility were randomly put into cages with five mice each. They were injected with respective tumour cells in the unit of cages, which were randomly selected. Tumour cells (5 × 10 6 ; mixed with Matrigel at a 1:1 ratio) were injected into mammary fat pads of age-matched athymic female nude mice (5 mice for each group based on power calculations, which will allow us to detect a ∼30% difference in tumour growth and/or glucose uptake between groups at the 95% confidence level). Tumour size was measured weekly using a calliper, and tumour volume was calculated using the standard formula: 0.54×L×W 2 , where L is the longest diameter and W is the shortest diameter. When tumours reached volumes of 150-200 mm 3 , mice were randomly divided into groups and intravenously injected with LINK-A or scrambled LNAs (25 mg kg −1 ) every other day for three times. Then mice were imaged and analysed with [ 18 F]FDG for in vivo glucose uptake. [ 18 F]FDG was administered via a single tail-vein injection; further PET/CT images were scanned and collected using the Inveon CT/PET system (Siemens). During the uptake period, mice were awake and maintained on a heating pad. Images were reconstructed using the two-dimensional ordered subsets expectation maximization (OSEM) algorithm. PET and CT image fusion and image analysis were performed using the software ASIPro 5.2.4.0 (Siemens). The investigators were not blinded to allocation during experiments and outcome assessment.
